Selected research
Market Analysis & Forecast
Global Pharma Ophthalmic Market Analysis and Forecast 2026-2032
Market perspective
The global Pharma Ophthalmic market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Pharma Ophthalmic is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Pharma Ophthalmic is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Pharma Ophthalmic is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Pharma Ophthalmic is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global manufacturers of Pharma Ophthalmic include Akorn, Allergan, Regeneron, Senju, Valeant, Bayer, Santen, Pfizer and Roche, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Pharma Ophthalmic, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Pharma Ophthalmic, also provides the sales of main regions and countries. Of the upcoming market potential for Pharma Ophthalmic, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Pharma Ophthalmic sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Pharma Ophthalmic market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Pharma Ophthalmic sales, projected growth trends, production technology, application and end-user industry.
Pharma Ophthalmic Segment by Company
Akorn
Allergan
Regeneron
Senju
Valeant
Bayer
Santen
Pfizer
Roche
Novartis
Pharma Ophthalmic Segment by Type
Retinal disorders drugs
Glaucoma drugs
Other ophthalmic drugs
Allergic, inflammatory and infective drugs
Dry eye drugs
Pharma Ophthalmic Segment by Application
Dry eye syndrome
Other ophthalmic indications
Glaucoma
Retinal diseases
Pharma Ophthalmic Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pharma Ophthalmic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pharma Ophthalmic and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pharma Ophthalmic.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Pharma Ophthalmic in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Pharma Ophthalmic manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pharma Ophthalmic sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Retinal disorders drugs
- Glaucoma drugs
- Other ophthalmic drugs
- Allergic, inflammatory and infective drugs
- Dry eye drugs
Applications
- Dry eye syndrome
- Other ophthalmic indications
- Glaucoma
- Retinal diseases
Companies covered
- Akorn
- Allergan
- Regeneron
- Senju
- Valeant
- Bayer
- Santen
- Pfizer
- Roche
- Novartis
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Pharma Ophthalmic Market by Type
- 1.2.1 Global Pharma Ophthalmic Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Retinal disorders drugs
- 1.2.3 Glaucoma drugs
- 1.2.4 Other ophthalmic drugs
- 1.2.5 Allergic, inflammatory and infective drugs
- 1.2.6 Dry eye drugs
- 1.3 Pharma Ophthalmic Market by Application
- 1.3.1 Global Pharma Ophthalmic Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Dry eye syndrome
- 1.3.3 Other ophthalmic indications
- 1.3.4 Glaucoma
- 1.3.5 Retinal diseases
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Pharma Ophthalmic Market Dynamics
- 2.1 Pharma Ophthalmic Industry Trends
- 2.2 Pharma Ophthalmic Industry Drivers
- 2.3 Pharma Ophthalmic Industry Opportunities and Challenges
- 2.4 Pharma Ophthalmic Industry Restraints
3 Global Market Growth Prospects
- 3.1 Global Pharma Ophthalmic Revenue Estimates and Forecasts (2021-2032)
- 3.2 Global Pharma Ophthalmic Revenue by Region
- 3.2.1 Global Pharma Ophthalmic Revenue by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Pharma Ophthalmic Revenue by Region (2021-2026)
- 3.2.3 Global Pharma Ophthalmic Revenue by Region (2027-2032)
- 3.2.4 Global Pharma Ophthalmic Revenue Market Share by Region (2021-2032)
- 3.3 Global Pharma Ophthalmic Sales Estimates and Forecasts 2021-2032
- 3.4 Global Pharma Ophthalmic Sales by Region
- 3.4.1 Global Pharma Ophthalmic Sales by Region: 2021 VS 2025 VS 2032
- 3.4.2 Global Pharma Ophthalmic Sales by Region (2021-2026)
- 3.4.3 Global Pharma Ophthalmic Sales by Region (2027-2032)
- 3.4.4 Global Pharma Ophthalmic Sales Market Share by Region (2021-2032)
- 3.5 US & Canada & Mexico
- 3.6 Europe
- 3.7 China
- 3.8 Asia (Excluding China)
- 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
- 4.1 Global Pharma Ophthalmic Revenue by Manufacturers
- 4.1.1 Global Pharma Ophthalmic Revenue by Manufacturers (2021-2026)
- 4.1.2 Global Pharma Ophthalmic Revenue Market Share by Manufacturers (2021-2026)
- 4.1.3 Global Pharma Ophthalmic Manufacturers Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Pharma Ophthalmic Sales by Manufacturers
- 4.2.1 Global Pharma Ophthalmic Sales by Manufacturers (2021-2026)
- 4.2.2 Global Pharma Ophthalmic Sales Market Share by Manufacturers (2021-2026)
- 4.2.3 Global Pharma Ophthalmic Manufacturers Sales Share Top 10 and Top 5 in 2025
- 4.3 Global Pharma Ophthalmic Sales Price by Manufacturers (2021-2026)
- 4.4 Global Pharma Ophthalmic Key Manufacturers Ranking, 2024 VS 2025 VS 2026
- 4.5 Global Pharma Ophthalmic Key Manufacturers Manufacturing Sites & Headquarters
- 4.6 Global Pharma Ophthalmic Manufacturers, Product Type & Application
- 4.7 Global Pharma Ophthalmic Manufacturers' Establishment Date
- 4.8 Market Competitive Analysis
- 4.8.1 Global Pharma Ophthalmic Market CR5 and HHI
- 4.8.2 2025 Pharma Ophthalmic Tier 1, Tier 2, and Tier 3
5 Pharma Ophthalmic Market by Type
- 5.1 Global Pharma Ophthalmic Revenue by Type
- 5.1.1 Global Pharma Ophthalmic Revenue by Type (2021 VS 2025 VS 2032)
- 5.1.2 Global Pharma Ophthalmic Revenue by Type (2021-2032) & (US$ Million)
- 5.1.3 Global Pharma Ophthalmic Revenue Market Share by Type (2021-2032)
- 5.2 Global Pharma Ophthalmic Sales by Type
- 5.2.1 Global Pharma Ophthalmic Sales by Type (2021 VS 2025 VS 2032)
- 5.2.2 Global Pharma Ophthalmic Sales by Type (2021-2032) & (W Units)
- 5.2.3 Global Pharma Ophthalmic Sales Market Share by Type (2021-2032)
- 5.3 Global Pharma Ophthalmic Price by Type
6 Pharma Ophthalmic Market by Application
- 6.1 Global Pharma Ophthalmic Revenue by Application
- 6.1.1 Global Pharma Ophthalmic Revenue by Application (2021 VS 2025 VS 2032)
- 6.1.2 Global Pharma Ophthalmic Revenue by Application (2021-2032) & (US$ Million)
- 6.1.3 Global Pharma Ophthalmic Revenue Market Share by Application (2021-2032)
- 6.2 Global Pharma Ophthalmic Sales by Application
- 6.2.1 Global Pharma Ophthalmic Sales by Application (2021 VS 2025 VS 2032)
- 6.2.2 Global Pharma Ophthalmic Sales by Application (2021-2032) & (W Units)
- 6.2.3 Global Pharma Ophthalmic Sales Market Share by Application (2021-2032)
- 6.3 Global Pharma Ophthalmic Price by Application
7 Company Profiles
- 7.1 Akorn
- 7.1.1 Akorn Company Information
- 7.1.2 Akorn Business Overview
- 7.1.3 Akorn Pharma Ophthalmic Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.1.4 Akorn Pharma Ophthalmic Product Portfolio
- 7.1.5 Akorn Recent Developments
- 7.2 Allergan
- 7.2.1 Allergan Company Information
- 7.2.2 Allergan Business Overview
- 7.2.3 Allergan Pharma Ophthalmic Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.2.4 Allergan Pharma Ophthalmic Product Portfolio
- 7.2.5 Allergan Recent Developments
- 7.3 Regeneron
- 7.3.1 Regeneron Company Information
- 7.3.2 Regeneron Business Overview
- 7.3.3 Regeneron Pharma Ophthalmic Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.3.4 Regeneron Pharma Ophthalmic Product Portfolio
- 7.3.5 Regeneron Recent Developments
- 7.4 Senju
- 7.4.1 Senju Company Information
- 7.4.2 Senju Business Overview
- 7.4.3 Senju Pharma Ophthalmic Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.4.4 Senju Pharma Ophthalmic Product Portfolio
- 7.4.5 Senju Recent Developments
- 7.5 Valeant
- 7.5.1 Valeant Company Information
- 7.5.2 Valeant Business Overview
- 7.5.3 Valeant Pharma Ophthalmic Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.5.4 Valeant Pharma Ophthalmic Product Portfolio
- 7.5.5 Valeant Recent Developments
- 7.6 Bayer
- 7.6.1 Bayer Company Information
- 7.6.2 Bayer Business Overview
- 7.6.3 Bayer Pharma Ophthalmic Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.6.4 Bayer Pharma Ophthalmic Product Portfolio
- 7.6.5 Bayer Recent Developments
- 7.7 Santen
- 7.7.1 Santen Company Information
- 7.7.2 Santen Business Overview
- 7.7.3 Santen Pharma Ophthalmic Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.7.4 Santen Pharma Ophthalmic Product Portfolio
- 7.7.5 Santen Recent Developments
- 7.8 Pfizer
- 7.8.1 Pfizer Company Information
- 7.8.2 Pfizer Business Overview
- 7.8.3 Pfizer Pharma Ophthalmic Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.8.4 Pfizer Pharma Ophthalmic Product Portfolio
- 7.8.5 Pfizer Recent Developments
- 7.9 Roche
- 7.9.1 Roche Company Information
- 7.9.2 Roche Business Overview
- 7.9.3 Roche Pharma Ophthalmic Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.9.4 Roche Pharma Ophthalmic Product Portfolio
- 7.9.5 Roche Recent Developments
- 7.10 Novartis
- 7.10.1 Novartis Company Information
- 7.10.2 Novartis Business Overview
- 7.10.3 Novartis Pharma Ophthalmic Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.10.4 Novartis Pharma Ophthalmic Product Portfolio
- 7.10.5 Novartis Recent Developments
8 North America
- 8.1 North America Pharma Ophthalmic Market Size by Type
- 8.1.1 North America Pharma Ophthalmic Revenue by Type (2021-2032)
- 8.1.2 North America Pharma Ophthalmic Sales by Type (2021-2032)
- 8.1.3 North America Pharma Ophthalmic Price by Type (2021-2032)
- 8.2 North America Pharma Ophthalmic Market Size by Application
- 8.2.1 North America Pharma Ophthalmic Revenue by Application (2021-2032)
- 8.2.2 North America Pharma Ophthalmic Sales by Application (2021-2032)
- 8.2.3 North America Pharma Ophthalmic Price by Application (2021-2032)
- 8.3 North America Pharma Ophthalmic Market Size by Country
- 8.3.1 North America Pharma Ophthalmic Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
- 8.3.2 North America Pharma Ophthalmic Sales by Country (2021 VS 2025 VS 2032)
- 8.3.3 North America Pharma Ophthalmic Price by Country (2021-2032)
- 8.3.4 United States
- 8.3.5 Canada
- 8.3.6 Mexico
9 Europe
- 9.1 Europe Pharma Ophthalmic Market Size by Type
- 9.1.1 Europe Pharma Ophthalmic Revenue by Type (2021-2032)
- 9.1.2 Europe Pharma Ophthalmic Sales by Type (2021-2032)
- 9.1.3 Europe Pharma Ophthalmic Price by Type (2021-2032)
- 9.2 Europe Pharma Ophthalmic Market Size by Application
- 9.2.1 Europe Pharma Ophthalmic Revenue by Application (2021-2032)
- 9.2.2 Europe Pharma Ophthalmic Sales by Application (2021-2032)
- 9.2.3 Europe Pharma Ophthalmic Price by Application (2021-2032)
- 9.3 Europe Pharma Ophthalmic Market Size by Country
- 9.3.1 Europe Pharma Ophthalmic Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
- 9.3.2 Europe Pharma Ophthalmic Sales by Country (2021 VS 2025 VS 2032)
- 9.3.3 Europe Pharma Ophthalmic Price by Country (2021-2032)
- 9.3.4 Germany
- 9.3.5 France
- 9.3.6 U.K.
- 9.3.7 Italy
- 9.3.8 Russia
- 9.3.9 Spain
- 9.3.10 Netherlands
10 China
- 10.1 China Pharma Ophthalmic Market Size by Type
- 10.1.1 China Pharma Ophthalmic Revenue by Type (2021-2032)
- 10.1.2 China Pharma Ophthalmic Sales by Type (2021-2032)
- 10.1.3 China Pharma Ophthalmic Price by Type (2021-2032)
- 10.2 China Pharma Ophthalmic Market Size by Application
- 10.2.1 China Pharma Ophthalmic Revenue by Application (2021-2032)
- 10.2.2 China Pharma Ophthalmic Sales by Application (2021-2032)
- 10.2.3 China Pharma Ophthalmic Price by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Pharma Ophthalmic Market Size by Type
- 11.1.1 Asia Pharma Ophthalmic Revenue by Type (2021-2032)
- 11.1.2 Asia Pharma Ophthalmic Sales by Type (2021-2032)
- 11.1.3 Asia Pharma Ophthalmic Price by Type (2021-2032)
- 11.2 Asia Pharma Ophthalmic Market Size by Application
- 11.2.1 Asia Pharma Ophthalmic Revenue by Application (2021-2032)
- 11.2.2 Asia Pharma Ophthalmic Sales by Application (2021-2032)
- 11.2.3 Asia Pharma Ophthalmic Price by Application (2021-2032)
- 11.3 Asia Pharma Ophthalmic Market Size by Country
- 11.3.1 Asia Pharma Ophthalmic Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
- 11.3.2 Asia Pharma Ophthalmic Sales by Country (2021 VS 2025 VS 2032)
- 11.3.3 Asia Pharma Ophthalmic Price by Country (2021-2032)
- 11.3.4 Japan
- 11.3.5 South Korea
- 11.3.6 India
- 11.3.7 Australia
- 11.3.8 Taiwan
- 11.3.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Pharma Ophthalmic Market Size by Type
- 12.1.1 SAMEA Pharma Ophthalmic Revenue by Type (2021-2032)
- 12.1.2 SAMEA Pharma Ophthalmic Sales by Type (2021-2032)
- 12.1.3 SAMEA Pharma Ophthalmic Price by Type (2021-2032)
- 12.2 SAMEA Pharma Ophthalmic Market Size by Application
- 12.2.1 SAMEA Pharma Ophthalmic Revenue by Application (2021-2032)
- 12.2.2 SAMEA Pharma Ophthalmic Sales by Application (2021-2032)
- 12.2.3 SAMEA Pharma Ophthalmic Price by Application (2021-2032)
- 12.3 SAMEA Pharma Ophthalmic Market Size by Country
- 12.3.1 SAMEA Pharma Ophthalmic Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
- 12.3.2 SAMEA Pharma Ophthalmic Sales by Country (2021 VS 2025 VS 2032)
- 12.3.3 SAMEA Pharma Ophthalmic Price by Country (2021-2032)
- 12.3.4 Brazil
- 12.3.5 Argentina
- 12.3.6 Chile
- 12.3.7 Colombia
- 12.3.8 Peru
- 12.3.9 Saudi Arabia
- 12.3.10 Israel
- 12.3.11 UAE
- 12.3.12 Turkey
- 12.3.13 Iran
- 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
- 13.1 Pharma Ophthalmic Value Chain Analysis
- 13.1.1 Pharma Ophthalmic Key Raw Materials
- 13.1.2 Raw Materials Key Suppliers
- 13.1.3 Manufacturing Cost Structure
- 13.1.4 Pharma Ophthalmic Production Mode & Process
- 13.2 Pharma Ophthalmic Sales Channels Analysis
- 13.2.1 Direct Comparison with Distribution Share
- 13.2.2 Pharma Ophthalmic Distributors
- 13.2.3 Pharma Ophthalmic Customers
14 Concluding Insights
15 Appendix
- 15.1 Reasons for Doing This Study
- 15.2 Research Methodology
- 15.3 Research Process
- 15.4 Authors List of This Report
- 15.5 Data Source
- 15.5.1 Secondary Sources
- 15.5.2 Primary Sources
- 15.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst